JAZZ News and Press, Jazz Pharmaceuticals plc From 03/20/24

2024-03-20 11:30:01 ET RBC Capital analyst issues UNDERPERFORM recommendation for JAZZ on March 20, 2024 10:00AM ET. The previous analyst recommendation was Underperform. JAZZ was trading at $124.43 at issue of the analyst recommendation. The overall analyst consensus : ...

NORTHAMPTON, MA / ACCESSWIRE / March 20, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals To mark International Women's Day, JAWS (Jazz Association of Women Supporters), the affinity forum created to promote the advancement and impact of women globally in the innovati...

NORTHAMPTON, MA / ACCESSWIRE / March 14, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals on LinkedIn In honor of U.S. Black History Month, JazzSoul, the affinity forum created to support Black employees and their allies and foster inclusive conversations at Jazz, cel...

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024 Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024 PR Newswire DUBLIN , March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasda...

2024-03-05 14:00:00 ET Summary Avadel's stock rose 51% post-buy recommendation, buoyed by Q4 earnings and a favorable royalty rate judgment versus Jazz Pharmaceuticals. Lumryz's market penetration and unique once-nightly dosing advantage are driving optimistic revenue forecasts an...

2024-03-03 02:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance PR Newswire – Total revenues of $3.8 billion in 2023 and $1 billion in 4Q23 – – 27% year-over-year revenue increase from combine...

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...

Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors PR Newswire Mr. Kennedy brings wealth of experience managing high growth organizations focused on creating value for shareholders DUBLIN , Feb. 27, 2024 /PRNewswire/ -- Jazz Pharmaceu...

2024-02-25 11:40:00 ET Summary Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. For the fourth quarter of 2023, Aristo...